Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 27

Zeitschriftenartikel

Peter, B.; Bibi, S.; Eisenwort, G.; Wingelhofer, B.; Berger, D.; Stefanzl, G.; Blatt, K.; Herrmann, H.; Hadzijusufovic, E.; Hoermann, G.; Hoffmann, T.; Schwaab, J.; Jawhar, M.; Willmann, M.; Sperr, W. R.; Zuber, J.; Sotlar, K.; Horny, H-P; Moriggl, R.; Reiter, A.; Arock, M. und Valent, P. (2018): Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. In: Leukemia, Bd. 32, Nr. 4: S. 1016-1022

Rabenhorst, A.; Sperr, W.; Elberink, J. Oude; Lange, M.; Gleixner, K.; Brazzelli, V.; Fontana, E.; Vos, B.; Gorska, A.; Reiter, A.; Schwaab, J.; Zanotti, R.; Bonadonna, P.; Triggiani, M.; Gotlib, J.; Doubek, M.; Jakob, T.; Kilbertus, A.; Sabato, V.; Zink, A.; Bretterklieber, A.; Jäkel, N.; Sotlar, K.; Horny, H.; Fortina, A. Belloni; Merante, S.; Niedoszytko, M.; Kluin-Nelemans, H.; Valent, P. und Hartmann, K. (2017): Age at disease onset has a major impact on clinical characteristics and course of mastocytosis. In: Experimental Dermatology, Bd. 26, Nr. 3, E6-E6

Valent, P.; Sotlar, K.; Blatt, K.; Hartmann, K.; Reiter, A.; Sadovnik, I.; Sperr, W. R.; Bettelheim, P.; Akin, C.; Bauer, K.; George, T. I.; Hadzijusufovic, E.; Wolf, D.; Gotlib, J.; Mahon, F.-X.; Metcalfe, D. D.; Horny, H.-P. und Arock, M. (2017): Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. In: Leukemia, Bd. 31, Nr. 4: S. 788-797

Rudnik, M.; Stellato, M.; Milleret, V.; Blyszczuk, P.; Maurer, B.; Klingel, K.; Henes, J.; Sotlar, K.; Ehrbar, M.; Distler, O. und Kania, G. (2017): The Role and Function of Monocyte-Derived Fibroblast-Like Cells in Multi-Organ Fibrosis in Systemic Sclerosis. In: Annals of the Rheumatic Diseases, Bd. 76: S. 88

Stellato, M.; Rudnik, M.; Renoux, F.; Pachera, E.; Kayalar, D.; Sotlar, K.; Klingel, K.; Henes, J.; Blyszczuk, P.; Distler, O. und Kania, G. (2017): Rescue from the Failing Heart in Systemic Sclerosis, a Novel Insight: Targeting Tgf-Beta/Fra2-Dependent Autophagy. In: Annals of the Rheumatic Diseases, Bd. 76: S. 86-87

Niedoszytko, M.; Gorska, A.; Nedoszytko, B.; Rabenhorst, A.; Sperr, W.; Elberink, Oude J.; Lange, M.; Gleixner, K.; Brazzelli, V; Fontana, E.; Vos, B.; Reiter, A.; Schwaab, J.; Zanotti, R.; Bonadonna, P.; Triggiani, M.; Gotlib, J.; Doubek, M.; Jakob, T.; Fuchs, D.; Sabato, V; Zink, A.; Bretterklieber, A.; Jäkel, N.; Sotlar, K.; Horny, H.; Fortina, Belloni A.; Merante, S.; Kluin-Nelemans, H.; Valent, P. und Hartmann, K. (2017): Impact of allergic disorders and anaphylaxis in mastocytosis: Preliminary data from a study of the European Competence Network on Mastocytosis (ECNM) registry. In: Allergy, Bd. 72: S. 212-213

Gorska, A.; Gruchala-Niedoszytko, M.; Niedoszytko, M.; Rabenhorst, A.; Sperr, W.; Elberink, Oude J.; Lange, M.; Gleixner, K.; Brazzelli, V; Fontana, E.; Vos, B.; Reiter, A.; Schwaab, J.; Zanotti, R.; Bonadonna, P.; Triggiani, M.; Gotlib, J.; Doubek, M.; Jakob, T.; Fuchs, D.; Sabato, V; Zink, A.; Bretterklieber, A.; Jäkel, N.; Sotlar, K.; Horny, H.; Fortina, Belloni A.; Merante, S.; Kluin-Nelemans, H.; Valent, P. und Hartmann, K. (2017): The body mass index is an indicator of advanced systemic mastocytosis: preliminary results from a registry project of the European Competence Network on Mastocytosis (ECNM) registry. In: Allergy, Bd. 72: S. 126-127

Valent, P.; Akin, C.; Hartmann, K.; George, T. I.; Sotlar, K.; Peter, B.; Gleixner, K. V.; Blatt, K.; Sperr, W. R.; Manley, P. W.; Hermine, O.; Kluin-Nelemans, H. C.; Arock, M.; Horny, H.-P.; Reiter, A. und Gotlib, J. (2017): Midostaurin: a magic bullet that blocks mast cell expansion and activation. In: Annals of Oncology, Bd. 28, Nr. 10: S. 2367-2376

Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H. P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C.; Fabarius, A.; Hofmann, W. K.; Valent, P.; Metzgeroth, G. und Reiter, A. (2016): Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis. In: Haematologica, Bd. 101: S. 559

Liedtke, C.; Gluz, O.; Nitz, U.; Christgen, M.; Sotlar, K.; Grischke, E.-M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Linder, C.; Kümmel, S.; Clemens, M.; Potenberg, J.; Peter, S.; Kohls, A.; Pelz, E.; Kates, R. E.; Würstlein, R.; Kreipe, H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Oncology Research and Treatment, Bd. 39: S. 53

Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A. (2016): Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. In: Oncology Research and Treatment, Bd. 39: S. 232

Bellos, F.; Sotlar, K.; Jeromin, S.; Haferlach, C.; Haferlach, T. und Kern, W. (2016): Assessment of CD30 expression on mast cells in systemic mastocytosis by immunohistochemistry versus multiparameter flow cytometry and correlation to clinical parameters. In: Oncology Research and Treatment, Bd. 39: S. 152

Naumann, N.; Jawhar, M.; Schwaab, J.; Metzgeroth, G.; Khaled, N.; Horny, H.-P.; Sotlar, K.; Valent, P.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Meggendorfer, M.; Cross, N. C. P.; Hofmann, W. K.; Reiter, A. und Fabarius, A. (2016): Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis. In: Oncology Research and Treatment, Bd. 39: S. 25

Jawhar, M.; Schwaab, J.; Meggendorfer, M.; Naumann, N.; Kluger, S.; Horny, H.-P.; Sotlar, K.; Haferlach, T.; Fabarius, A.; Hofmann, W.-K.; Reiter, A. und Metzgeroth, G. (2016): Mast cell leukemia: clinical heterogeneity, molecular aberrations and prognostic factors. In: Oncology Research and Treatment, Bd. 39: S. 24

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E. und Harbeck, N. (2016): The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. In: Current Medical Research and Opinion, Bd. 32, Nr. 7: S. 1217-1224

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, A.; Kates, R. E.; Pelz, E. und Harbeck, N. (2016): Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Oncology Research and Treatment, Bd. 39: S. 49

Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A. (2016): Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. In: Leukemia, Bd. 30, Nr. 12: S. 2342-2350

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Bd. 76

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, J.; Kates, R. E.; Pelz, E. und Harbeck, N. (2016): Prosigna®(R) results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Cancer Research, Bd. 76

Rudnik, M.; Stellato, M.; Blyszczuk, P.; Pachera, E.; Dobrota, R.; Maurer, B.; Klingel, K.; Henes, J.; Sotlar, K.; Distler, O. und Kania, G. (2016): Micrornas as Potential Regulators of Monocyte Differentiation and Function in Heart Fibrosis in Systemic Sclerosis. In: Annals of the Rheumatic Diseases, Bd. 75: S. 167 [PDF, 59kB]

Fehm, T.; Schultz, S.; Bartsch, H.; Petat-Dutter, K.; Kahlert, S.; Sotlar, K.; Niederacher, D. und Neubauer, H. (2016): Verification of the breast cancer progression-associated miRNA hsa-miR-199a-5p using NanoString (R) platform. In: Cancer Research, Bd. 76

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Bd. 76

Scheel, C. H.; Linnemann, J. R.; Miura, H.; Meixner, L. K.; Irmier, M.; Kloos, U. J.; Hirschi, B.; Bartsch, H. S.; Sass, S.; Beckers, J.; Theis, F. J.; Gabka, C. und Sotlar, K. (2016): A force-sensitive organoid assay to quantify regenerative potential of single primary human mammary cells. In: Cancer Research, Bd. 76

Jawhar, M.; Schwaab, J.; Schnittger, S.; Meggendorfer, M.; Pfirrmann, Markus; Sotlar, K.; Horny, H. P.; Metzgeroth, G.; Kluger, S.; Naumann, N.; Haferlach, C.; Haferlach, T.; Valent, P.; Hofmann, W. K.; Fabarius, A.; Cross, N. C. und Reiter, A. (2016): Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. In: Leukemia, Bd. 30, Nr. 1: S. 136-143

Schwaab, J.; Schnittger, S.; Sotlar, K.; Walz, C.; Fabarius, A.; Pfirrmann, Markus; Kohlmann, A.; Grossmann, V.; Meggendorfer, M.; Horny, H. P.; Valent, P.; Jawhar, M.; Teichmann, M.; Metzgeroth, G.; Erben, P.; Ernst, T.; Hochhaus, A.; Haferlach, T.; Hofmann, W. K.; Cross, N. C. und Reiter, A. (2013): Comprehensive mutational profiling in advanced systemic mastocytosis. In: Blood, Bd. 122, Nr. 14: S. 2460-2466

Horny, H. -P.; Sotlar, K. und Valent, P. (2012): Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology. In: International Archives of Allergy and Immunology, Nr. 1: S. 1-5 [PDF, 106kB]

Horny, H. -P.; Sotlar, K. und Valent, P. (2010): Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review. In: Pathobiology, Nr. 4: S. 169-180 [PDF, 1MB]

Diese Liste wurde am Sat Mar 16 19:25:11 2024 CET erstellt.